Description: <b>Cucurbitacin</b>, produced by some plants, especially Cucurbitaceae, as a defense against herbivores. Toxic compound that can form in plants in the gourd family (Zucchini, Squash).<br>
Cucurbitacins have been shown to inhibit the growth of various cancer cell lines by interfering with cell cycle progression. Cucurbitacins can affect various signaling pathways involved in cancer progression, such as the NF-κB and STAT3 pathways, which are often dysregulated in cancer.<br>
<br>
<p><b>Cucurbitacin</b> — Cucurbitacins are a family of highly oxygenated tetracyclic triterpenoids produced mainly by Cucurbitaceae plants as bitter defensive metabolites. They are best treated as a compound class rather than a single molecule; common research abbreviations include CuB, CuD, CuE, CuI, CuQ, and Cuc IIa. Their formal classification is plant-derived triterpenoid natural products with experimental cytotoxic, cytostatic, anti-inflammatory, and pathway-modulating activity. In oncology, cucurbitacin B, E, I, Q, and IIa are the most commonly studied members. Mechanistic profile dominated by ACLY↓, STAT3/JAK signaling, cytoskeletal disruption, cell-cycle arrest, apoptosis, and context-dependent chemosensitization.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>JAK/STAT3 pathway suppression, especially inhibition of constitutive STAT3 activation in tumor models.</li>
<li>Actin cytoskeleton disruption and mitotic spindle interference, contributing to loss of motility, mitotic failure, and G2/M arrest.</li>
<li>Cell-cycle arrest and apoptosis through caspase activation, mitochondrial stress, cytochrome c release, BCL-2 family modulation, and cyclin/CDK disruption.</li>
<li>ROS-dependent cytotoxic stress in selected models, usually as a secondary or downstream death-amplifying mechanism rather than a universal primary target.</li>
<li>Suppression of invasion, migration, angiogenesis-like behavior, and cancer stemness programs through STAT3, MAPK, Notch, NF-κB, and related axes.</li>
<li>Chemosensitization in preclinical models, especially reported potentiation of gemcitabine and cisplatin effects.</li>
<li>Metabolic/lipid-axis effects including ACLY-related relevance, but this appears less central than STAT3/cytoskeleton/apoptosis based on the broader literature.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral systemic translation is constrained by low solubility, low oral bioavailability, tissue distribution, narrow therapeutic window, and nonspecific toxicity. Cucurbitacin B has reported absolute oral bioavailability of approximately 10% in rat PK work, so in-vitro potency should not be assumed to translate directly to safe systemic exposure. Although CuB displays potent activity against tumor cells, its non-selective toxicity has limited its clinical applications.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer studies use purified cucurbitacins at nanomolar to micromolar concentrations in cell lines and xenografts. Common in-vitro exposure levels may exceed reliably achievable and tolerable human systemic exposure from oral ingestion. This is a concentration-driven small-molecule class, not a field-based or device-based modality.</p>
<p><b>Clinical evidence status:</b> Preclinical. Evidence is substantial across cell-line and animal oncology models, but there is no established FDA, EMA, or Health Canada approved cucurbitacin anticancer drug. Human use is limited by toxicity concerns, lack of standardized clinical oncology dosing, and absence of robust cancer RCT evidence.</p>
<h3>Cucurbitacin Cancer Mechanism Table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>JAK STAT3 oncogenic transcription</td>
<td>STAT3 phosphorylation ↓; STAT3 survival transcription ↓; apoptosis ↑</td>
<td>STAT signaling may also be affected in activated immune or epithelial cells (context-dependent)</td>
<td>R,G</td>
<td>Core anticancer survival-pathway suppression</td>
<td>Best-supported central axis for CuB, CuI, CuE, and CuQ. Effects are not necessarily selective for malignant cells if exposure is high.</td>
</tr>
<tr>
<td>2</td>
<td>Actin cytoskeleton and mitotic spindle</td>
<td>F-actin organization disrupted; actin aggregation ↑; mitotic spindle defects ↑; motility ↓</td>
<td>Cytoskeletal toxicity risk ↑ in proliferating or barrier tissues (dose-dependent)</td>
<td>P,R</td>
<td>Motility blockade, mitotic stress, and cytotoxicity</td>
<td>Cytoskeletal modulation is a major mechanism, especially for CuE, CuI, CuB, and Cuc IIa. This mechanism may contribute to both anticancer activity and nonspecific toxicity.</td>
</tr>
<tr>
<td>3</td>
<td>Cell cycle arrest</td>
<td>G2/M arrest ↑; cyclin B1/CDK programs ↓; p21/p27 ↑ in some models</td>
<td>Proliferating normal cells may be vulnerable (dose-dependent)</td>
<td>R,G</td>
<td>Cytostatic and pro-apoptotic checkpoint stress</td>
<td>Frequently reported across breast, lung, colon, hepatoma, neuroblastoma, and pancreatic cancer models.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial apoptosis</td>
<td>Caspase activation ↑; cytochrome c release ↑; BCL-2 ↓; mitochondrial stress ↑</td>
<td>Mitochondrial injury risk ↑ at high exposure</td>
<td>G</td>
<td>Execution of tumor-cell death</td>
<td>Often downstream of STAT3 inhibition, cytoskeletal stress, ROS stress, or cell-cycle blockade.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial ROS increase</td>
<td>ROS ↑; oxidative stress-mediated apoptosis ↑ (model-dependent)</td>
<td>Oxidative injury risk ↑ if systemic exposure is high</td>
<td>R,G</td>
<td>Secondary death amplification</td>
<td>Important in selected models such as colon cancer, but not the most universal primary mechanism for the class.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB inflammatory survival signaling</td>
<td>NF-κB activity ↓; inflammatory survival programs ↓ (context-dependent)</td>
<td>Inflammatory signaling may be reduced, but epithelial irritation/toxicity remains a concern</td>
<td>R,G</td>
<td>Anti-inflammatory and anti-survival modulation</td>
<td>Useful as a secondary axis; should not be ranked above STAT3 or cytoskeletal effects for the overall class.</td>
</tr>
<tr>
<td>7</td>
<td>MAPK PI3K AKT signaling</td>
<td>MAPK and PI3K/AKT signaling ↓ in selected models; proliferation and invasion ↓</td>
<td>Broad kinase-network perturbation possible (context-dependent)</td>
<td>R,G</td>
<td>Growth and survival suppression</td>
<td>Reported in hepatoma, glioma-related, neuroblastoma, and other models, but appears model-specific rather than universal.</td>
</tr>
<tr>
<td>8</td>
<td>Notch cancer stemness axis</td>
<td>Notch signaling ↓; CSC markers ↓; xenograft growth ↓ in colon cancer models</td>
<td>Normal stem/progenitor signaling could be affected (context-dependent)</td>
<td>G</td>
<td>Anti-stemness and tumor-growth suppression</td>
<td>Mechanistically meaningful but less broadly established than STAT3/cytoskeleton/cell-cycle mechanisms.</td>
</tr>
<tr>
<td>9</td>
<td>Migration invasion angiogenesis programs</td>
<td>Migration ↓; invasion ↓; tube formation/neovascularization markers ↓</td>
<td>Wound-healing and endothelial effects possible (dose-dependent)</td>
<td>G</td>
<td>Anti-metastatic and anti-angiogenic phenotype</td>
<td>Often secondary to STAT3, MAPK, cytoskeletal, and inflammatory pathway effects.</td>
</tr>
<tr>
<td>10</td>
<td>Glycolysis lipid metabolism and ACLY</td>
<td>ACLY/lipid-metabolism relevance ↓ or implicated (limited direct cucurbitacin-specific support)</td>
<td>Metabolic effects uncertain</td>
<td>G</td>
<td>Possible metabolic-growth constraint</td>
<td>STAT3, cytoskeletal, cell-cycle, and apoptosis mechanisms.</td>
</tr>
<tr>
<td>11</td>
<td>Chemosensitization</td>
<td>Gemcitabine response ↑; cisplatin response ↑ in selected preclinical models</td>
<td>Combination toxicity risk ↑ (dose-dependent)</td>
<td>G</td>
<td>Preclinical drug-potentiation strategy</td>
<td>Potentially important, but not clinically validated as a standard adjunct. Timing, dose, and tumor context would be critical.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Potent in vitro cytotoxicity may not translate safely to systemic therapy</td>
<td>GI irritation, mucosal injury, systemic toxicity, and narrow therapeutic window are major concerns</td>
<td>G</td>
<td>Limits clinical deployment</td>
<td>Low oral bioavailability, poor solubility, nonspecific toxicity, and lack of robust human oncology trials make cucurbitacins experimental leads rather than practical clinical agents at present.</td>
</tr>
</table>
<p><b>TSF legend:</b></p>
<p>P: 0–30 min</p>
<p>R: 30 min–3 hr</p>
<p>G: >3 hr</p>